Lonza Group AG (LZAGY) Q4 2023 Earnings Call Transcript Summary
Lonza Group AG (LZAGY) Q4 2023 Earnings Call Transcript Summary
The core The following is a summary of the Lonza Group AG (LZAGY) Q4 2023 Earnings Call Transcript:
以下是隆沙集团股份公司（LZAGY）2023年第四季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Lonza reported group sales of CHF 6.7 billion in 2023, showing a growth of 10.9%.
Profits stood at CHF 655 million in 2023, declining by 46% year-on-year, primarily due to divestment gains and impairment losses.
The core EBITDA remained steady at CHF 2 billion, resulting in a margin of 29.8%.
The free cash flow for 2023 was CHF 329 million, backed by net working capital improvements and CapEx prioritization.
Net debt rose to CHF 1.1 billion due to investments in organic growth and the share buyback program.
A proposed dividend increase of 14% to CHF 4 per share is planned for 2023.
龙沙报告称，2023年集团销售额为67亿瑞士法郎，增长10.9％。
2023年利润为6.55亿瑞士法郎，同比下降46％，这主要是由于撤资收益和减值损失。
核心息税折旧摊销前利润稳定在20亿瑞士法郎，利润率为29.8％。
2023年的自由现金流为3.29亿瑞士法郎，这得到了净营运资本改善和资本支出优先排序的支持。
由于对有机增长和股票回购计划的投资，净负债增至11亿瑞士法郎。
计划在2023年将股息增加14％，至每股4瑞士法郎。
Business Progress:
业务进展：
The company observed strong performance in Biologics and Small Molecules divisions, which generated over 70% of the revenue with a margin exceeding 30% each.
About 130 new CDMO customers and 350 new clinical and commercial programs were signed in 2023, indicating significant market operations progress.
The company foresees high capacity utilization over the next five years, led by sustained manufacturing services demand and successful Phase I drug candidates.
Sustainability efforts are being bolstered, with reductions in emission, energy, and water intensity accomplished.
For 2024, the company expects high single-digit underlying sales growth and a core EBITDA margin in the high 20s (27% - 29%), driven by sturdy commercial CDMO business performance and anticipated recovery in Capsules & Health Ingredients.
There are expansion plans for growth investments in Europe and Americas, and an improved core EBITDA margin within the 32% - 33% range by 2028 is projected.
Jean-Marc Hyvert is proposed to be the new Chairman of Lonza, as decided at the forthcoming AGM in May.
该公司观察到生物制剂和小分子部门的强劲表现，这些部门创造了70％以上的收入，利润率各超过30％。
2023年签署了约130个新的CDMO客户和350个新的临床和商业项目，这表明市场运营取得了重大进展。
该公司预计，在持续的制造服务需求和成功的I期候选药物的带动下，未来五年的产能利用率将很高。
可持续发展工作正在得到加强，排放、能源和水强度均已降低。
该公司预计，2024年的基础销售额将实现较高的个位数增长，核心息税折旧摊销前利润率将达到20年代的最高水平（27％-29％），这要归因于稳健的商业CDMO业务表现以及胶囊和健康成分的预期复苏。
欧洲和美洲都有增长投资的扩张计划，预计到2028年，核心息税折旧摊销前利润率将提高到32％至33％的范围内。
根据即将于5月举行的股东周年大会的决定，提议让-马克·海弗特出任隆沙的新任董事长。
More detailed: LONZA GROUP AG UNSP ADR EACH REP 0.1 ORD IR
Tips: This article is generated by AI and the accuracy of the content can not be fully guaranteed. For more and comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成，无法完全保证内容的准确性。欲了解更多全面的详情，请访问投资者关系网站。本文仅供投资者参考，不提供任何指导或建议建议。
